Autopsy report · NCT01109615

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Lacking effect of treatment”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 11 months before it stopped.
40 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Vejle Hospital
Sponsor type: University, hospital or other
Conditions: Metastatic Colorectal Cancer
Interventions: Pemetrexed; Gemcitabine
Participants: 40
Sites: 1
Countries: Denmark

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.